Latest Amylyx Pharmaceuticals News & Updates

See the latest news and media coverage for Amylyx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Amylyx Pharmaceuticals (Amylyx)

Biopharmaceutical company developing novel therapies

amylyx.com
Headquarters
Cambridge, United States
Company type
Public company
Number of employees
150–200

Last updated

Latest news about Amylyx Pharmaceuticals (Amylyx)

In short: Amylyx Pharmaceuticals advanced its endocrine and rare disease pipeline following the withdrawal of its ALS treatment and a $6.5 million settlement.

Company announcements

  • Amylyx

    Amylyx reports Q1 2026 financial results

    R&D expenses rise to $27.6M, net loss $41.3M. LUCIDITY trial enrollment complete, topline data expected Q3 2026. Cash runway into 2028.

  • Amylyx

    Amylyx announces U.S. Expanded Access Program for avexitide

    The program provides access to eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Avexitide is in Phase 3 LUCIDITY trial with data expected Q3 2026.

  • Amylyx

    Amylyx completes enrollment in Phase 3 LUCIDITY trial

    The trial enrolled 78 participants for avexitide in post-bariatric hypoglycemia. Topline data expected in Q3 2026.

  • Amylyx

    Amylyx reports Q4 and full-year 2025 financial results

    Recruitment completes for Phase 3 LUCIDITY trial of avexitide in PBH, with topline data expected Q3 2026. Cash runway extends into 2028. Net loss narrows to $144.7M.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Amylyx

Track Amylyx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Amylyx competitors & trending companies

Browse news for competitors to Amylyx and other trending companies.